SureTrader Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 4/29/2016 3:54:51 PM - Followers: 164 - Board type: Free - Posts Today: 4

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
CVM News: CEL-SCI Featured on The RedChip Money Report Airing on Newsmax TV 04/08/2016 09:00:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/05/2016 05:02:35 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/05/2016 04:59:29 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/05/2016 04:56:27 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/05/2016 04:54:17 PM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8177   hopefully the recent positive press on immuno treatments georgebailey 04/29/16 03:54:51 PM
#8176   Yeah, probably some 31 patients. Kami_ss 04/29/16 03:27:12 PM
#8175   Should be past 780 on Monday. trickledownfacists 04/29/16 03:22:48 PM
#8174   Pathetic volume. Looking forward to the numbers early Kami_ss 04/29/16 01:01:08 PM
#8173   From Inventiv's quarterly report under "Risks"...... Our insurance may trickledownfacists 04/28/16 08:22:47 PM
#8172   Yes, for less than we paid for the Foxwoods Man 04/27/16 07:08:42 AM
#8171   Yes, for less than we paid for the dbernet 04/26/16 08:40:01 PM
#8170   My thinking on this is WHO for the Turney 04/26/16 04:58:00 PM
#8169   They most likely will expire worthless and they Foxwoods Man 04/26/16 01:25:42 PM
#8168   The CVM warrants are trading like investors think Turney 04/26/16 12:20:54 PM
#8167   More cancers falling to immunotherapy NEW ORLEANS — New trickledownfacists 04/25/16 10:16:40 PM
#8166   I know it's a stretch but the second trickledownfacists 04/23/16 08:07:46 PM
#8165   stockcharts.com/def/servlet/SharpChartv05.ServletDriver?chart=CVM,plamdan mick 04/23/16 03:14:07 PM
#8164   Interesting logic. With that logic you should never Kami_ss 04/23/16 09:42:20 AM
#8163   What an UGLY chart... ed2000 04/22/16 01:49:33 PM
#8162   If I had to guess more shorts are trickledownfacists 04/19/16 08:42:56 PM
#8161   ...and their study is for relapsed head and Foxwoods Man 04/19/16 05:01:25 PM
#8160   Their study is also nearer to completion than trickledownfacists 04/19/16 04:40:32 PM
#8159   Different studies different variables.... But I see where trickledownfacists 04/19/16 04:39:53 PM
#8158   Interim results presented today (Tuesday) show Foxwoods Man 04/19/16 04:30:57 PM
#8157   Thoughts.....? http://www.eurekalert.org/pub_releases/2016-04/iocr-iif041916.ph trickledownfacists 04/19/16 04:13:31 PM
#8156   Dude, you brought up a thought and I Kami_ss 04/17/16 10:55:13 AM
#8155   CVM ????? potential is here/ mick 04/16/16 05:08:22 PM
#8154   Cel-Sci Corp. ($0.00 (CVM) mick 04/16/16 05:07:33 PM
#8153   i am here, not much reporting/ cvm mick 04/16/16 05:07:19 PM
#8152   Its up to the courts to decide if Turney 04/15/16 02:14:33 PM
#8151   Sure, but there should still be some merit Kami_ss 04/15/16 01:46:18 PM
#8150   You know in this litigious day and age Turney 04/15/16 12:25:04 PM
#8149   I don't think this is a valid concern Kami_ss 04/15/16 10:10:13 AM
#8148   I hope we get our money from PharmaNet Turney 04/15/16 07:29:33 AM
#8147   THAT would be a good thing ;) Foxwoods Man 04/14/16 01:33:04 PM
#8146   Somebody must have read article in paper today. Turney 04/14/16 01:08:50 PM
#8145   ON THE MARKET: 10-bagger potential as CEL-SCI closes trickledownfacists 04/14/16 11:35:31 AM
#8144   Article today re CVM in Smallcapinsightsdotcom MsMom1 04/14/16 11:24:21 AM
#8143   Re Cel-Sci and M. D. Anderson: three Paleman 04/14/16 10:56:38 AM
#8142   MD Anderson links hepatitis C to greater risk trickledownfacists 04/14/16 09:32:31 AM
#8141   Sorry I had not read entire article it Turney 04/14/16 08:40:38 AM
#8140   Houston Chronicle today reports M.D. Anderson has found Turney 04/14/16 08:27:41 AM
#8139   The same when Geert speaks....no clue why Foxwoods Man 04/13/16 04:27:34 PM
#8138   That confirms it.... Foxwoods Man 04/13/16 04:26:45 PM
#8137   if do you will know more/ /\ 'Cel-Sci (CVM)' mick 04/13/16 03:48:15 PM
#8136   Everytime there is a positive article about CVM steve2150 04/13/16 03:22:07 PM
#8135   Are you trying to show that you know Foxwoods Man 04/13/16 02:49:10 PM
#8134   Great article....... Sharon di Stefano CEL-SCI's Manufacturing Of Cancer-Kill trickledownfacists 04/13/16 01:30:49 PM
#8133   Mick, I was worried, where were you? Kami_ss 04/13/16 01:28:59 PM
#8132   CVM News: CEL-SCI Featured on The RedChip Money mick 04/13/16 01:23:03 PM
#8131   Cel-Sci Corp. ($0.00 (CVM) mick 04/13/16 01:22:56 PM
#8130   Seeking Alpha posted a new article about CVM: Kami_ss 04/13/16 12:50:32 PM
#8129   CEL-SCI Corporation (NYSE MKT: CVM) was selected as Trade789 04/13/16 09:54:53 AM
#8128   Read about the $250 million on USA Today, steve2150 04/13/16 08:36:50 AM
PostSubject